Tyra biosciences reports second quarter 2025 financial results and highlights

- dosed first patient in surf302 for intermediate risk non-muscle invasive bladder cancer (ir nmibc) - - cash, cash equivalents, and marketable securities of $296.3 million at q2 2025; runway through at least 2027 - carlsbad, calif. , aug. 14, 2025 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, today reported financial results for the second quarter ended june 30, 2025, and highlighted recent corporate progress.
TYRA Ratings Summary
TYRA Quant Ranking